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INTRODUCTION:  
Due to advances in chronobiology, chronopharmacology 
and global market constraints, the traditional goal of 
pharmaceutics, that is  designing drug delivery system 
with a constant drug release rate is becoming obsolete for 
certain diseases. Nowadays, concept of 
chronopharmaceutics has emerged, wherein, research is 
devoted to the design and evaluation of drug delivery 
systems that release a therapeutic agent at a rhythm that 
ideally match the biological requirement of a given 
disease therapy
1
.
 
By timing drug administration, plasma 
peak is obtained at an optimal time and the number of 
doses per day can be reduced. Saturable first-pass 
metabolism and tolerance development can also be 
avoided
2
. The diseases currently targeted for 
chronomodulated formulations include asthma, arthritis, 
duodenal ulcer, cancer, diabetes, cardiovascular diseases, 
hypercholesterolemia, ulcer and neurological diseases
3
. 
Morning stiffness associated with pain at the time of 
awakening is a diagnostic criterion of the rheumatoid 
arthritis (RA). In patients with RA, inflammation induced 
changes in synovial fluid composition, oedema of the 
synovium and periarticular structures as well as 
redistribution of interstitial fluid while sleeping, 
contribute to clinical stiffness of the joints that is most 
prominent in the morning. Chronopharmacotherapy for 
RA has been recommended to ensure that the highest 
blood levels of the drug  coincide with peak pain and 
stiffness
4
. 
Lornoxicam, a congener of tenoxicam, is a novel NSAID 
belonging to the oxicam group
5
 with extremely potent 
anti-inflammatory and analgesic activities
6,7
. It is widely 
used for the symptomatic treatment of pain and 
inflammation in patients with rheumatoid arthritis and 
osteoarthritis
8
.  
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ABSTRACT:  
In view of chronobiological considerations of rheumatoid arthritis, the present study deals with the design and evaluation of 
multiparticulate system for the chronomodulated delivery of lornoxicam.  The basic design is based on the Pulsincap 
technology and consisted of formaldehyde treated insoluble hard gelatin capsule body filled with tripolyphosphate cross-linked 
chitosan microspheres of lornoxicam and sealed with a hydrogel tablet plug. The entire device was enteric coated, so as to 
prevent the variable gastric emptying time. The microspheres were found to be discrete, nearly spherical with rough surface 
characteristics.  Particle size, encapsulation efficiency and release rate of lornoxicam from the microspheres are dependent on 
the fabrication conditions of the microencapsulation. FT-IR, DSC and XRD studies revealed the compatibility of the drug with 
the excipients used.  The exposure of hard gelatine capsule bodies with formaldehyde for a period of 12 hrs was found to be 
optimum in maintaining the intactness of the capsule bodies in the simulated GI fluids. The lag time of the designed delivery 
system varied from 3-7 hrs and depended on the nature and concentration of the plugging material. The ejection of the plug was 
delayed with increase in the polymer concentration. Among the two polymers studied as plugging materials, guar gum 
exhibited better control in maintaining the lag time compared to xanthan gum. From the study it can be concluded that, the lag 
time be efficiently tailored by varying the concentrations of the polymers in the hydrogel plug for the chronomodulated delivery 
of lornoxicam.  
Key Words: Rheumatoid arthritis; Lornoxicam; Microspheres; Chronomodulated delivery systems; Hydrogel plug; Lag time. 
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However, lornoxicam's usefulness is limited due to its 
short half-life that ranges from 3 to 5 h
9,10
. Due to its 
rapid elimination rate, frequent administration of 
lornoxicam is needed to achieve long lasting and 
constant pain relief.  
In our previous studies we have reported the pH 
dependent solubility of lornoxicam which indicated 
better solubility in the higher pH pertaining to the 
colonic region
11
. Hence, in light of these facts, it is 
desirable to design the delivery system that produces the 
peak drug levels that ideally that matches the cirrcadiam 
rhythum of the rheumatoid arthritis resulting in better 
therapeutic outcome.  
Compared to single-unit dosage forms, multiparticlate 
systems like microspheres exhibit more uniform 
distribution and absorption of the drug in the 
gastrointestinal tract, reduced local irritation, higher 
colonic residence time, more predictable gastric 
emptying and also eliminates unwanted intestinal 
retention of polymeric material
12,13
.  Chitosan is an 
interesting biopolymer to prepare microspheres owing to 
its unique polymeric cationic character, good 
biocompatibility, non-toxicity, biodegradability, 
mucoadhesiveness and also due to its absorption 
enhancing effect
14,15
. Thus, the present study deals with 
the design and evaluation of multiparticulate system for 
the chronomodulated delivery of lornoxicam with an 
aim to achieve desired levels of the drug in the early 
morning hours for the effective management of RA. The 
chronomodulated delivery system was based on 
modified Pulsincap technology using TPP cross-linked 
chitosan microspheres loaded with lornoxicam and 
suitable hydrogel plugs.  
MATERIALS AND METHODS:  
Chitosan (Chitoclear®, 95% deacetylated) was obtained 
as gift sample from Primex Ltd, Iceland. Lornoxicam 
pure drug was generously supplied by Sun Pharma Ltd., 
Vadodhara. TPP was purchased from Molychem Ltd 
Hyderabed. Guar gum and xanthan gum were purchased 
from Himedia Laboratories Pvt Ltd, Mumbai. Hard 
gelatine capsules were generously supplied by Elegant 
Drugs Pvt Ltd, Hubli, Karnataka. All other chemicals 
and reagents were of analytical grade and were 
purchased from SD fine chemicals, Mumbai. 
Preparation of microspheres: 
Lornoxicam loaded chitosan microspheres were 
prepared by ionic gelation technique using TPP as cross-
linking agent. Briefly, 2% w/v chitosan solution was 
prepared using 1% aqueous acetic acid by stirring 
overnight on a magnetic stirrer. Accurately weighed 
quantity of lornoxicam was dispersed uniformly into the 
chitosan solution using the magnetic stirrer for 2h and 
further subjected for ultasonication (15 min) to remove 
the air bubbles. The drug containing chitosan solution 
was dropped into the gently agitated aqueous TPP 
solution with a disposable syringe (22 G) at the rate of 
1ml/min using digital over head stirrer. Microspheres 
were instantaneously formed and after predetermined 
period of time, microspheres were decanted from the 
dispersion medium and washed several times with 
distilled water to remove any surface adhering TPP. The 
microspheres thus obtained were dried at room 
temperature for 24h and stored in a desiccator for further 
use
16,17
. The details of formulation and process variables 
studied are given Table No: 1 
Characterization of Microspheres 
Particle size and surface topography 
 The size of the prepared microspheres was analysed 
using optical microscopy fitted with a calibrated eye 
piece micrometer. The mean of 100 microspheres was 
noted as average particle size
18
. The surface topography 
of the microspheres was studied using scanning electron 
microscopy (JEOL, JSM-6360, Japan). Microspheres 
were mounted on aluminium specimen stubs using 
double sided adhesive tape and coated with platinum 
under vacuum. The morphology of the microspheres 
was observed at acceleration voltage of 10 kV at 
different magnifications. 
Fourier tranform –infrared (FT-IR) spectral studies: 
 Pure drug, drug-excipients physical mixture and drug 
loaded microspheres were analyzed using Fourier 
transformer infrared spectrophotometer (IR Affinity 1 
model, Shimazdu Corporation, Japan, with diffuse 
reflectance scan sampling method). The samples were 
triturated with KBr and scanned over wave number 
range of 4000 to 400 cm
-1
. FT-IR spectra were analyzed 
for functional groups and drug polymer interactions. 
X-ray diffraction (XRD) analysis: 
 The effect of microencapsulation process on drug 
crystallinity was studied using XRD analysis. XRD 
patterns of pure drug, physical mixture and 
microspheres were recorded on X-ray diffractometer 
(XRD 6000, Shimadzu corporation, Japan) using Ni-
filtered, CuK radiation, a voltage of 40 Kv and current 
of 30mA. The scanning speed employed was 4˚/min 
over the 10˚ to 80˚ diffraction angle range. Microspheres 
were triturated to fine powder before performing the 
analysis.  
Differential scanning calorimetric (DSC) studies: 
The pure drug, drug-excipients physical mixture and 
drug loaded microspheres were subjected to differential 
scanning calorimeter (DSC, SIECKO, model-6300, 
Japan). The samples were sealed in aluminium pans and 
heated at a constant rate of 10
0
C/ min over a temperature 
range of 20-300 
0
C. Inert atmosphere was maintained by 
purging nitrogen gas at a flow rate of 10 ml/min. 
Encapsulation efficiency: Crushed microspheres 
equivalent to 8 mg of lornoxicam was accurately 
weighed and transferred to a 100ml volumetric flask 
containing 50ml of phosphate buffer of pH 7.4 and the 
volume was  made up to the mark using the same buffer 
solution. The flask was stirred on a thermostatic water 
bath (Remi Equipments Ltd., Mumbai) at room 
temperature for 24h to extract the entrapped drug. The 
content was filtered and after suitable dilution, the 
absorbance was noted on a UV spectrophotometer (UV-
1700, Shimadzu Corporation, Japan) at 377.0 nm using 
phosphate buffer of pH 7.4 as blank. Triplicate readings 
for each batch were noted and the average was 
determined as drug content of the microspheres
16,18
. 
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In vitro drug release: 
The release of lornoxicam from the microspheres was 
studied using USP type II dissolution apparatus (TDT-
08L, Electrolab dissolution tester). Microspheres 
equivalent to 8mg of lornoxicam were taken into the 
basket and the release studies were carried out under the 
following conditions; media: 900 ml of phosphate buffer 
of pH 6.8; temperature: 37 ±0.5 ˚C; speed: 100 rpm.  At 
fixed interval of time, aliquots were withdrawn and 
replaced with fresh dissolution media to maintain the 
constant volume. The concentration of drug released at 
different time intervals was then determined by 
measuring the absorbance at 376.5 nm against blank 
using UV spectrophotometer. 
 
Table 1: Composition, Yield, Encapsulation Efficiency and Particle size of Lornoxicam loaded chitosan 
microspheres (n=3) 
 Variables 
 
Yield (%) Actual Drug 
content(mg)* 
Encapsulation 
Efficiency (%) 
Particle Size 
(µm) 
Code Core: coat  constant: 
2% TPP,  
pH 8.5, 
 30 min 
 
 
C1 1:2 78.57(2.11) 4.51(0.14) 56.33 (1.8) 762.66 (7.41) 
C2 1:4 80.3(1.96) 4.84 (0.21) 60.45 (2.65) 794.99(6.47) 
C3 1:6 83.21(1.46) 5.22(0.14) 65.29(1.76) 829.35(5.12) 
C4 1:8 85.48(1.59) 5.75(0.14) 71.86(1.84) 855.14(2.83) 
 
pH of the  
medium 
constant: 
1:8, 
2% TPP,  
30 min 
    
H1 6.0 86.39(1.36) 6.03(0.18) 75.32(2.27) 789.73(7.9) 
H2 4.0 87.25(1.43) 6.45(0.25) 80.59(3.13) 741.24(7.91) 
H3 2.0 89.58(1.28) 7.08(0.16) 88.46(2.05) 733.05(6.01) 
 TPP % (w/v ) constant: 
1:8, 
pH 2.0,   
30 min 
    
P1 4 92.28(1.56) 7.3(0.11) 91.29(1.47) 719.22(8.82) 
P2 6 94.89(1.69) 7.68(0.10) 95.97(1.29) 702.81(9.6) 
P3 8 97.44(1.48) 7.7(0.13) 96.3(1.67) 678.32(5.55) 
 
Reaction time 
(min) 
constant: 
1:8, 
8% TPP, 
pH 2.0 
    
T1 45 97.58(1.55) 7.73(0.11) 96.59(1.43) 659.25(4.63) 
T2 60    97.19(1.7) 7.63(0.11) 95.39(1.45) 621.67(7.19) 
T3 90 96.45(1.41) 7.29(0.29) 91.19(3.62) 615.32(3.21) 
 
Design of the chronotherapeutic system
19
: 
The design of the chrnotherapeutic system involved 
following steps: 
i. Cross-linking of hard gelatine capsules: About 100 
hard gelatin capsules of size ‘2’ were taken and their 
bodies and caps were separated. Then, the bodies 
were treated with formaldehyde vapours to render 
them insoluble in gastro intestinal fluids while the 
caps remained untreated. Twenty-five millilitres of 
15% (v/v) formaldehyde was taken into desiccator 
and a pinch of potassium permanganate was added to 
it to generate formalin vapors. The empty bodies of 
hard gelatin capsule were placed over wire mesh and 
then exposed to formaldehyde vapors. The desiccator 
was tightly closed thereby exposing the capsule 
bodies to formaldehyde vapours for the specified 
period of time (4-12hrs) and dried at 50°C for 30 min 
to ensure complete reaction between gelatin and 
formaldehyde vapors. The bodies were then dried at 
room temperature for another 12hrs to facilitate 
removal of residual formaldehyde. The formaldehyde 
treated bodies were joined with untreated caps and 
stored in a polythene bag.  
ii. Optimization of formaldehyde treatment: The 
disintegration of the capsule bodies depend on the 
duration of formaldehyde exposure. Hence, cross-
linking time was optimized by exposing the capsules 
bodies to the formaldehyde vapours for 4, 8 and 12 
hrs. The bodies and the untreated caps were joined 
and subjected for disintegration test (Electrolab ED-
2L, Servewell Instruments Pvt Ltd, Bengaluru). The 
untreated gelatine capsules were also subjected for 
dinintegration study for the comparison purpose. The 
disintegration test was carried out for 2, 3 and up to 
24 hrs in 0.1N HCl, phosphate buffer of pH 6.8 and 
7.4 respectively. The time at which the capsules 
disintegrated were noted.  
iii. Preparation of Hydrogel plug: Direct compression 
method was used to prepare the hydrogel tablet plug. 
The composition of different tablet plugs used in the 
design of chronotherapeutic systems is shown in 
Table 2. Natural polymers like guar gum and xanthan 
gum along with other excipients were utilized in the 
preparation of the plug. The plug ingredients 
(polymers and lactose) were mixed for 10 minutes 
using mortar and pestle. Magnesium stearate 
(2%w/w) was added to the previous mixture and 
further blended for 5 minutes and compressed using 
Rotary compression machine (Rimek Mini Press-1, 
Karnavathi Engineering Ltd, Gujarat).  
iv. Capsule filling, plugging, sealing and enteric 
coating: Optimized Microspheres equivalent to 8 mg 
of lornoxicam was manually loaded in to the bodies 
by hand filling. After filling with the microspheres, 
the mouth of the formaldehyde treated bodies were 
plugged with the prepared hydrogel plugs and closed 
with the untreated caps. The joint of the body and cap 
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of the capsules was sealed with a small amount of 5% 
ethyl cellulose ethanolic solution. The sealed capsules 
were enteric coated by dip coating method with 4% 
HPMCP 55 in 4:1 (v/v) mixture of 
dichloromethane:acetone, plasticized with 
dibutylphthalate (0.75%), to prevent variable gastric 
emptying
20
. Coating was repeated until an 8–12% 
increase in weight is obtained. % weight gain of the 
capsules before and after coating was determined.  
                
Table 2: Composition of tablet plugs using guar gum and xanthan gum as lag time modifiers. 
Batch 
code 
GG XG Spray Dried 
Mannitol 
Mg. 
Stearate 
Total 
Weight 
LG1 60 --- 38 2 100 
LG2 50 --- 48 2 100 
LG3 40 --- 58 2 100 
LG4 30  68 2 100 
LX1 --- 60 38 2 100 
LX2 --- 50 48 2 100 
LX3 --- 40 58 2 100 
LX4 --- 30 68 2 100 
 
Evaluation of Chronotherapeutic system: 
Test for formaldehyde treated empty capsule bodies: 
Various physical tests such as, identification attributes, 
visual defects, dimension changes, solubility studies 
were carried out on the formaldehyde treated empty 
capsule bodies. 
Qualitative chemical test for free formaldehyde: 
Standard formaldehyde solution used is formaldehyde 
solution (0.002 w/v) and sample solution is prepared by 
dissolving formaldehyde treated bodies (about 25 in 
number) in distilled water. The content was stirred for 1 
h with a magnetic stirrer, to solubilize the free 
formaldehyde. The solution was then filtered into a 50 
ml volumetric flask, washed with distilled water and 
volume was made up to 50 ml with the washings. In 
brief, to 1 ml of sample solution, 9 ml of distilled water 
was added. One milliliter of resulting solution was taken 
into a test tube and mixed with 4 ml of water and 5 ml of 
acetone reagent. The test tube was warmed in a water 
bath at 40 °C and allowed to stand for 40 min. The 
solution was not more intensely colored than a reference 
solution prepared at the same time and in the same 
manner using 1 ml of standard solution in place of the 
sample solution. The comparison was made by 
examining tubes down their vertical axis. 
In vitro release studies: Dissolution studies were 
carried out by using USP XXIV dissolution apparatus 
(paddle method). Capsules were tied to paddle with a 
cotton thread so that the capsule should be immersed 
completely in dissolution media but not float. In order to 
simulate the pH changes along the GI tract, three 
dissolution media with pH 1.2, 7.4 and 6.8 were 
sequentially used, referred to as sequential pH change 
method. When performing experiments, the pH 1.2 
medium was first used for 2 h (since the average gastric 
emptying time is 2 h), then removed and the fresh pH 
7.4 phosphate buffer saline (PBS) was added. After 3 h 
(average small intestinal transit time is 3 h), the medium 
was removed and fresh phosphate buffer of pH 6.8 was 
added for subsequent hours. Nine hundred milliliters of 
the dissolution medium was used at each time. Rotation 
speed was 100 rpm and temperature was maintained at 
37±0.5 
o
C. Five milliliters of dissolution media was 
withdrawn at predetermined time intervals and fresh 
dissolution media was replaced. The withdrawn samples 
were analyzed at 372.5 nm, 376.5 nm and 377.5 nm for 
acidic medium, phosphate buffer of pH 6.8 and 7.4 
respectively by UV absorption spectroscopy and the 
cumulative percentage release was calculated over the 
sampling times. 
RESULTS AND DISCUSSION: 
Particle Size: The average particle size of the 
microspheres is given in Table No 1. Particle size 
increased with increase in core: coat ratio which could 
be due to more amount of coat material in same volume 
of liquid droplet.  Whereas particle size decreased for 
the microspheres prepared at lower pH of TPP solution 
which could be attributed to the pH dependent ionization 
of TPP resulting in more ionically cross-linked 
microspheres. Particle size also reduced with an increase 
in the cross-linking agent concentration as well as extent 
of cross-linking
21
.  
SEM photographs revealed that the prepared 
microspheres were discrete, broadly spherical with 
rough surface characteristics (Fig. 1). The surface of the 
microspheres was dense without any porous structures. 
The morphological studies also revealed the presence of 
few cracks on the surface of the microspheres. Our 
observations are concordant with the findings of other 
researchers who reported rough surface characteristics of 
chitosan microspheres prepared by the ionotropic 
gelation technique using TPP as cross-linking agent
22,23
. 
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Figure 1: SEM Photographs of TPP cross-linked chitosan microspheres. A. Individual microsphere and its 
magnified surface topography B. 200X, C. 500X and D. 1000X. 
 
Encapsulation efficiency: 
The encapsulation efficiency increased with increase in 
core: coat ratio which could be due to more availability 
of active TPP binding sites in the polymeric chains 
leading to higher encapsulation efficiency. When the pH 
of the dispersion medium was changed from its original 
alkaline, a significant improvement in the lornoxicam 
entrapment was observed which may be due to its poor 
solubility in lower pH
11
. The encapsulation efficiency 
was also increased for the microspheres prepared at 
higher TPP concentrations. However, slight reduction in 
the entrapment of lornoxicam was noted when the 
curing time was increased from 30 to 90minutes.  
FT-IR studies:  
The FT-IR spectra of physical mixture, drug loaded 
microspheres were compared with the FT-IR spectrum 
of pure drug (Fig: 2). The pure drug lornoxicam 
exhibited its characteristic absorption bands at 3099.61 
cm
-1 
due to aromatic/heterocyclic C-H stretching and at 
2926.01 cm
-1 
due to C-H stretching of CH3 group. The 
other prominent absorption bands appeared at 1647.21 
cm
-1
 due to stretching vibrations of C=O of CONH, 
1618.28 due to aromatic C=C and C=N stretching. 
Bending vibrations of NH group in the secondary amine 
were observed at 1593.20 and 1544.96 cm
-1
 whereas 
aromatic C=C skeleton stretching vibrations were 
observed at 1500.62 cm
-1
. The peaks at 1423.47 cm
-1 
and 
1327.03 cm
-1 
corresponds to O=S=O group, 790 cm
-1 
due to substituted aromatic rings, 765.74 cm
-1 
due to C-
Cl stretching vibrations. The IR spectra of physical 
mixture and drug loaded microsphere formulation 
exhibited all the characteristic absorption bands as that 
of pure drug lornoxicam without any significant 
variations. It is clear from the spectra that, the drug has 
not undergone any kind of interactions with the 
excipients used and retained its identity both in its 
physical mixture as well as in its formulation.  
XRD studies:  
The XRD patterns of lornoxicam, its physical mixture 
and drug loaded microspheres are shown in Fig: 3. The 
X-Ray powder diffractogram of pure drug exhibited a 
series of intense peaks which is indicative of its 
crystalline nature. The typical crystalline peaks of the 
drug in the physical mixture were clearly visible without 
any significant changes in the positions and relative 
intensities, thereby ruling out any interaction between 
the drug and the excipients. However, the diffractogram 
of the lornoxicam loaded microspheres showed peaks of 
diminished intensities indicating that the drug is 
molecularly dispersed in the polymeric matrix or might 
have undergone amorphization during the microsphere 
preparation
21
. 
DSC Studies: Differential Scanning Calorimetric 
analysis was also performed in order to establish the 
identity and integrity of drug in its pure form, physical 
mixture and also in the microsphere formulation. The 
thermogram of the pure drug lornoxicam showed an 
exothermic peak exhibiting its sharp melting point at 
231.8 ˚C which corresponds to its reported range24. The 
thermogram of the physical mixture revealed the 
existence of the lornoxicam exothermic peak at 228.6 ˚C 
indicating the absence of interaction between the drug 
and the excipients. However, noticeable broadening of 
the peak intensity was observed which could be due to 
the presence of the formulation excipients. The 
thermogram of drug loaded microspheres revealed the 
disappearance of the characteristic exothermic peak of 
lornoxicam. This suggests that, the drug was 
molecularly dispersed in the polymeric matrix of the 
microspheres or existed in an amorphous form. This fact 
was also well supported by our XRD studies. From the 
study, it can be concluded that there is no interaction of 
the drug with the polymer and other excipients used in 
the formulation. 
Patil et al                                           Journal of Drug Delivery & Therapeutics. 2015; 5(3):62-71 67 
© 2011-15, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                       CODEN (USA) 
 
Figure 2: FT-IR Spectra of A. Pure drug lornoxicam, B. Physical Mixture, C. Drug loaded microspheres. 
 
Figure 3: XRD Patterns of A. Pure drug lornoxicam, B. Physical Mixture, C. Drug loaded microspheres 
 
Figure 4: DSC Thermograms of A. Pure drug lornoxicam, B. Physical Mixture, C. Drug loaded microspheres. 
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In vitro drug release studies: 
Drug release from the TPP cross-linked chitosan 
microspheres was largely influenced by formulation 
(core: coat ratio and TPP concentration) and process (pH 
of the dispersion medium and reaction time) variables. 
The plots of cumulative percentage drug release versus 
time for different formulations are shown in Fig No 5 
and 6. Initially, the microspheres prepared with various 
core: coat ratios and at fixed TPP concentration 
(2%w/v), pH of the dispersion medium (original pH 8.5) 
and reaction time (30 min) were subjected for 
dissolution studies. Dissolution studies revealed the 
decrease in drug release with increasing core: coat ratio 
in the microspheres. This could be due to more efficient 
entanglement of the drug within the polymeric matrix of 
the microspheres composed of higher levels of coat 
material.  
The results of the dissolution study of the microspheres 
prepared at different pH conditions revealed that, as the 
pH of the dispersion medium was lowered from its 
original pH 8.5 to pH 2.0, the drug release from the 
microspheres drastically reduced. On the other hand, 
microspheres prepared at higher pH exhibited faster 
drug release. This could be due to the fact that, at lower 
pH, ionization degree of TPP and chitosan are high and 
complete cross-linking occurs without deprotonation
22,
 
thereby leading to more controlled drug release. The 
drug release from the microspheres proportionately 
decreased with increase in cross-linking agent 
concentration and duration of cross-linking. This could 
be due to more cross-linking of the polymeric chains 
with increased TPP concentration and also increased 
duration of microsphere exposure to the coagulant 
medium would provide more reaction time which leads 
to more efficient cross-linking and thus reducing the 
drug release. Overall, the results of dissolution studies 
revealed that, drug release from the microspheres can be 
efficiently tailored by altering the formulation and 
process parameters. Microspheres of H2 batch with 
release rate of more than 60% at the end of 6
th 
hr and 
continued till the end of 12 hrs was selected for the 
design of chronomodulated delivery of lornoxicam. The 
selected batch also exhibited good encapsulation 
efficiency and surface characteristics.  
 
 
Figure 5: Effect of core: coat ratio on in vitro release of lornoxicam from TPP cross-linked chitosan 
microspheres. 
 
Figure 6: Effect of fabrication conditions on in vitro release of lornoxicam from TPP cross-linked chitosan 
microspheres. 
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Mechanism of drug release: The drug release 
mechanism was studied with respect to zero order, first 
order, Higuchi model and Korsemayer and Peppas 
models. The coefficient values were found to be higher 
for Higuchi model (0.9952-0.9666) than Peppas model 
(0.9899-0.8903) followed by first order (0.9668-0.8517) 
and zero order (0.9907-0.8848) which is an indicative of 
diffusion controlled drug release. The n values of Peppas 
equation were in the range of 0.4031-0.8938 suggesting 
the anomalous (non-Fickian) release mechanism. 
Evaluation of chronomodulated system: 
Formaldehyde treated empty capsule bodies: 
Formaldehyde treatment has been employed to modify 
the solubility of the gelatin capsules. Exposure to 
formalin vapors results in an unpredictable decrease in 
solubility of gelatin owing to the cross linkage of the 
amino groups in the gelatin molecular chain with 
aldehyde groups of formaldehyde by Schiff‟s base 
condensation. In about 100 capsule bodies treated with 
formaldehyde, about 8-10 bodies were found to be 
shrunk or distorted. Slight decrease in length and 
diameter of the capsule bodies was observed after 
treatment with the formaldehyde. The formaldehyde 
capsules were also tested for the presence of free 
formaldehyde. The sample solution was not more 
intensely colored than the standard solution inferring 
that less than 20μg/ml of free formaldehyde per 25 
capsules, taken for test. 
Optimization of cross-linking conditions: 
From the disintegration studies it was observed that, the 
untreated capsules (both body and cap) dissolved within 
10-12 minutes where as the dissolution of the treated 
bodies depended upon the duration of cross-linking with 
formaldehyde. The capsule bodies treated for 4hrs with 
formaldehyde vapours become soft and sticky mass was 
formed at the end of 2hrs disintegration study in 0.1N 
HCl solution and completely dissolved within 1hr when 
exposed to phosphate buffer of pH 6.8. The capsule 
bodies exposed to formaldehyde vapours for 8hrs did not 
disintegrated but become soft at the end of 10 hrs 
disintegration study. However, the bodies treated with 
formaldehyde for 12hrs remained intact throughout the 
disintegration study of 24 hrs and were selected for the 
design of chronotherapeutic systems. Various other 
workers have also adopted 12 hrs formaldehyde 
treatment in the efficient cross-linking of the hard 
gelatine capsules
25
.   
In vitro release studies: All the designed 
chronotherapeutic systems of lornoxicam with guar gum 
and xanthan gum as plugging materials were subjected 
for the dissolution studies and the results are depicted in 
Fig 7and 8. From the graphs it is clear that, all the 
capsules remained intact in the acidic pH for the initial 2 
hrs of the dissolution studies, indicating the integrity of 
the enteric coating with HPMCP. Further, when the 
dissolution medium was changed to pH 7.4, the enteric 
coating along with the soluble cap dissolved thereby 
exposing the hydrogel plug to the dissolution medium. 
The exposed hydrogel plug then, absorbed the 
surrounding fluid, swelled and released the drug through 
the swollen matrix. After this, the hydrogel plug turned 
out into a soft mass, which was then easily ejected out of 
the capsule body there by releasing the lornoxicam 
loaded chitosan microspheres in the simulated colonic 
fluid (phosphate buffer of pH 6.8). With all the 
formulations, there was absolutely no drug release in pH 
1.2, thus indicating the efficacy of enteric coating with 
HPMCP.     
The polymer nature and concentration had profound 
impact on the swelling and ejection of the hydrogel plug. 
Irrespective of the polymer used, as its concentration 
was increased, there was a proportionate delay in the 
wetting and also the complete ejection of the plug.  
Guar gum (GG) as a hydrogel plugging material in four 
different concentrations like 60, 50, 40 and 30 mg were 
used in the formulations LG1, LG2, LG3 and LG4 
respectively. The cumulative drug release at the end of 
7
th
, 6
th
, 5
th
 and 4
th
 hr was found to be 4.56, 3.35, 6.18 and 
9.58% with LG1, LG2, LG3 and LG4 respectively after 
which the plug were completely ejected and all the 
microspheres were released. It was observed that, as the 
polymer concentration in the hydrogel plug was 
increased, there was a proportionate delay in the ejection 
of the hydrogel plug. This could be attributed to delayed 
wetting and swelling of the hydrogel material at the 
higher polymeric concentration. Overall, with all the 
formulations containing guar gum as a plugging 
material, a lag period of 4-7 hrs was achieved and there 
after the drug release was spread over a period of 18 hrs 
in a controlled manner. 
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In another set of formulations, xanthan gum as a 
hydrogel plugging material in four different 
concentrations like 60, 50, 40 and 30 mg were used in 
LX1, LX2, LX3 and LX4 respectively. The cumulative 
drug release at the end of 6
th
 and 5
th
 hr was found to be 
8.33 and 10.56%  with LX1 and LX2 respectively after 
which the plug were completely ejected, whereas 7.33 
and 5.88% drug was released at the end of 4
th
 hr and 3
rd
 
hr dissolution study in case of LX3 and LX4 
respectively. Similarly as observed with guar gum, 
increase in xanthan gum concentration resulted in 
proportionate delay in the ejection of the hydrogel plug. 
However, the lag time observed in case of xanthan gum 
was shorter when compared to that of guar gum. This 
could be probably due to higher swelling nature of 
xanthan gum leading to early ejection of the plug when 
compared to the guar gum. Overall, from the study it 
can concluded, guar gum and xanthan gum as plugging 
materials provides the concentration depended lag time 
for the chronomodulated delivery of lornoxicam that 
could be utilized in the better management of 
rheumatoid arthritis.   
  
 
 
CONCLUSION:  
The TPP cross-linked chitosan microspheres were found 
to be discrete, nearly spherical with rough surface 
characteristics.  Particle size, encapsulation efficiency 
and release rate are dependent on the fabrication 
conditions of the microspheres. The developed 
microspheres were successfully utilized in the 
development of the chronomodulated delivery systems 
of lornoxicam. FT-IR, DSC and XRD studies revealed 
the compatibility of the drug with the excipients used.  
The exposure of hard gelatine capsule bodies with 
formaldehyde for a period of 12 hrs was found to be 
optimum in maintaining the intactness of the capsule 
bodies in the simulated GI fluids. The ejection of the 
plug from the chrnomodulated delivery system 
depended on the nature of polymer and their 
concentration. The ejection of the plug delayed with 
increase in the polymer concentration and among the 
two polymers studied as plugging materials, guar gum 
exhibited better control in maintaining the lag time 
compared to xanthan gum. Overall, from the study it can 
be concluded that, the lag time can be efficiently tailored 
for the chronomodulated delivery of lornoxicam by 
varying the concentrations of the polymers in the 
hydrogel plug.  
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